Secukinumab (AIN457) was also developed for neutralizing IL-17A, which is a proinflammatory cytokine mainly secreted from T helper cells (Th-17) and currently in Phase III clinical trials for evaluation of its therapeutic efficacy and safety in RA treatment [41]. Here, IL17A is linked to rheumatoid arthritis.